A Phase Ib, Open-label, Multicenter Study of Oral LXH254 in Combination With Oral LTT462 in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs LTT 462 (Primary) ; LXH 254 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 18 Jun 2017 Planned primary completion date changed from 31 Dec 2018 to 30 Sep 2017.
- 17 May 2017 Planned primary completion date changed from 30 Sep 2017 to 31 Dec 2018.
- 24 Apr 2017 Planned End Date changed from 13 Dec 2019 to 31 Dec 2018.